Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. The company’s first program aimed at addressing immunogenicity to AAV gene therapies is expected to enter clinical trials in early 2021 in partnership with AskBio for the treatment of methylmalonic acidemia (MMA), a rare metabolic disorder. A wholly-owned program focused on addressing IgA nephropathy driven by ImmTOR and a therapeutic enzyme is also in development among additional product candidates. Selecta recently licensed its Phase 3 clinical product candidate, SEL-212, in chronic refractory gout to Sobi.
Location: United States, Massachusetts, Watertown
Member count: 51-200
Total raised: $152.6M
Founded date: 2007
Investors 4
| Date | Name | Website |
| - | ND CAPITAL | nd.capital |
| - | I2BF Globa... | i2bf.com |
| - | Vivo Capit... | vivocapita... |
| - | Solasta Ve... | solasta-ve... |
Funding Rounds 6
| Date | Series | Amount | Investors | Deal News |
| 01.09.2020 | - | $35M | - | - |
| 08.09.2015 | Series E | $38M | - | finsmes.co... |
| 15.10.2014 | - | $20M | - | vcnewsdail... |
| 19.06.2014 | - | $9.35M | - | finsmes.co... |
| 27.10.2011 | - | $47.25M | - | finsmes.co... |
| 17.08.2010 | Grant | $3M | - | finsmes.co... |
Mentions in press and media 22
| Date | Title | Description | Category | Author | Source |
| 21.03.2023 | Phase 3 DI... | Phase 3 DISSOLVE Program of SE... | - | - | news.cisio... |
| 07.07.2022 | Manufac... | Managing a co-developed drug i... | - | Tyler Patc... | endpts.com... |
| 06.04.2022 | Selecta Bi... | WATERTOWN, Mass., April 06, 20... | - | - | globenewsw... |
| 10.01.2022 | Selecta Bi... | WATERTOWN, Mass. and BOSTON, J... | - | - | marketscre... |
| 08.11.2021 | AI upstar... | Boston AI-focused biotech Dee... | - | Paul Schlo... | endpts.com... |
| 26.10.2021 | Selecta Bi... | BOSTON and WATERTOWN, Mass., O... | - | - | marketscre... |
| 09.09.2021 | Seattle st... | Cyrus Biotechnology has severa... | - | Charlotte ... | geekwire.c... |
| 01.09.2020 | Selecta Bi... | WATERTOWN, Mass., Sept. 01, 20... | - | - | citybizlis... |
| 29.06.2016 | The biotec... | There was a time after the 20... | Financing | John Carro... | endpts.com... |
| 25.05.2016 | Langer’s n... | After a strong year with a str... | Biotech | - | fiercebiot... |
Show more